CTOs on the Move

Anthelio Healthcare

www.antheliohealth.com

 
Anthelio Healthcare Solutions Inc. is much more than a healthcare IT company. We are a single source provider of world-class technology solutions for the healthcare industry with a 15-year history of excellence. Our innovative services and products make it easier for our customers to do what they do best – deliver outstanding patient care. Our company was built on the foundation that healthcare is our only business, uniquely positioning us as one of the very few companies who focus solely on the needs of our healthcare customers and their patients. We take great pride in maintaining the highest levels of ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

ResearchPoint Global

ResearchPoint Global is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nutex Health

The Future of Healthcare Nutex Health Inc. is a technology-enabled health management company with two divisions: Business Development Marketing Operations Coordination Legal Human Resources Accounting Billing & Collections Nutex Health Inc. is a techno...

Kootenai Medical Center

Kootenai Health provides a comprehensive range of medical services to patients in north Idaho, eastern Washington, Montana and the Inland Northwest at several facility locations. The main campus at Kootenai Health is located in Coeur d`Alene, Idaho and includes a 299-bed community-owned hospital. By providing outstanding health care, Kootenai Health repeatedly earns regional and national recognition.

Emancipet

Emancipet is on a mission to make veterinary care affordable and accessible for everyone. Visit our site to find your closest clinic & explore our services

Kolltan

Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.